Drug interactions
Doxorubicin + Lorlatinib
Severity: Minor
Doxorubicin and Lorlatinib: minor interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Lorlatinib is a moderate CYP3A inducer and may modestly lower exposure to substrates, but doxorubicin is cleared mainly by carbonyl reductase, CYP2D6 and P-gp rather than primarily CYP3A4. The clinical impact on doxorubicin is uncertain and probably small.
What this interaction means in plain words
Doxorubicin and Lorlatinib have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.
Doxorubicin belongs to Oncology; Lorlatinib belongs to Oncology.
Why it happens
Possible induction of CYP3A and transporters by lorlatinib; effect on doxorubicin not well established.
What to do
No dose change is required; monitor for reduced antitumor response and unexpected toxicity.
What to ask your pharmacist
- Is there anything I should notice while taking both?
- Do I need to tell my doctor at the next visit?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Doxorubicin and Lorlatinib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Doxorubicin
Other interactions of Lorlatinib
- Amobarbital + Lorlatinib Contraindicated
- Apalutamide + Lorlatinib Contraindicated
- Butabarbital + Lorlatinib Contraindicated
- Carbamazepine + Lorlatinib Contraindicated
- Enzalutamide + Lorlatinib Contraindicated
- Fosphenytoin + Lorlatinib Contraindicated
Frequently asked questions
Can I take Doxorubicin with Lorlatinib?
MediHelp rates the interaction as minor. Doxorubicin and Lorlatinib have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. Lorlatinib is a moderate CYP3A inducer and may modestly lower exposure to substrates, but doxorubicin is cleared mainly by carbonyl reductase, CYP2D6 and P-gp rather than primarily CYP3A4. The clinical impact on doxorubicin is uncertain and probably small.
How serious is the interaction between Doxorubicin and Lorlatinib?
MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: No dose change is required; monitor for reduced antitumor response and unexpected toxicity.
What other medicines interact with Doxorubicin?
MediHelp also lists interactions of Doxorubicin with, for example, Adenovirus types 4 and 7 live, Belatacept, Cobicistat. The full list is on the Doxorubicin page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
